Phase 2 N=70 A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Change From Baseline to Week 8 in Forced Vital Capacity (FVC) — -0.02; -0.03; -0.07 liters — p=0.9086
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
Phase 1 N=38 A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
Healthy Volunteers
Primary: Maximum Observed Concentration (Cmax) of GDC-0134. — 5.56; 4.45; 2.66; 2.68 uM
Phase 2 N=422 Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant
A/Vietnam/H5N1 Influenza Virus
Primary: Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination. — 34; 41; 34; 34 occurrences
Phase 2 N=108 Citalopram for Cocaine Dependence
Cocaine Dependence
Primary: Number of Participants Who Are Cocaine Abstinent During the Last 2 Weeks of Treatment (Weeks 8-9), as Assessed by Urine Test — 0; 4; 2 Participants
Phase 3 N=40 The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study
Hemorrhage · Soft Tissue Bleeding
Primary: Absolute Time to Haemostasis — 4.0; 4.0 Minutes
Phase 2 N=47 Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
Treatment of Depression in Adults With Parkinson's Disease (PD)
Primary: Change From Baseline to Week 8 in HAMD-17 (Hamilton Depression Scale -17 Items) Total Score — 19.2; 8.1 score on a scale — p=<0.0001
N/A N=198 LifeVest Trends Validation Protocol
Heart Failure
Primary: Distance Traveled in Six Minute Walk Test — 306; 296 meters
Phase 3 N=43 Zevalin-beam for Aggressive Lymphoma
Non-Hodgkin's Lymphoma
Primary: Overall Survival — 91; 62 percentage of participants
Phase 2 N=309 A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32 — 95; 94; 91…
Phase 1 N=21 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
N/A N=42 ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
Alzheimer Disease
Primary: Acute Safety — 2 participants
Phase 2 N=73 A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 9; 9; 15 participants
Phase 2 N=14 Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious Adverse Events (SAEs) — 14; 5; 8; 1 Participants
N/A N=44 A Diagnostic Study of the Advanced Endoscopy to Detect Early Esophageal Cancer
Esophageal Neoplasms
Primary: Accuracy — 89; 70 Percentage of accuracy